GSK plc (GSK) Stock Forecast
GSK analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 3.56 / 5 from 9 analysts
- Price target
- $60.51 average of analyst targets
- Upside to target
- +22.2% from the latest close
- Next earnings
- October 28, 2026 EPS estimate $1.40
- 52-week range
- $43.24 – $61.18
GSK analyst ratings
9 analystsNumber of analysts at each rating.
GSK price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
GSK earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.33 | $1.31 | $1.34 | $1.46 | −8.8% | 2 |
| Current fiscal year (2026) | $4.72 | $4.64 | $4.87 | $4.71 | +0.2% | 5 |
| Next fiscal year (2027) | $4.92 | $4.72 | $5.09 | $4.72 | +4.3% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
GSK revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $8.81B | $8.71B | $8.93B | +3.0% | 7 |
| Current fiscal year (2026) | $33.91B | $33.50B | $34.24B | +3.8% | 21 |
| Next fiscal year (2027) | $35.52B | $34.44B | $37.78B | +4.7% | 20 |
GSK EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
GSK revenue: reported and forecast
GSK EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.41 | $1.34 | $1.35 | $1.35 | $1.33 | −6.1% | 0 up · 2 down |
| Current fiscal year (2026) | $4.79 | $4.75 | $4.79 | $4.80 | $4.72 | −1.4% | 0 up · 3 down |
| Next fiscal year (2027) | $5.13 | $5.14 | $4.98 | $5.02 | $4.92 | −4.0% | 0 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
GSK earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; GSK beat in 11 of 12.
What analysts expect from GSK
9 analysts cover GSK; their consensus rating is buy (3.56 on a 1–5 scale, where 5 is a strong buy). The average price target is $60.51, 22.2% above the latest close of $49.51. Analysts expect earnings of $4.72 per share for 2026, +0.2% from a year earlier. For 2027 the average estimate is $4.92 per share on revenue of $35.5 billion. GSK beat the EPS estimate in 11 of the last 12 quarters.
Related: GSK income statement, GSK chart. See the GSK stock overview for the latest quote and news.
GSK forecast FAQ
What is GSK's price target?
The average analyst price target for GSK is $60.51, 22.2% above the latest close of $49.51.
Is GSK a buy, hold or sell?
Of 9 analysts covering GSK, 3 rate it a strong buy, 1 a buy, 4 a hold, 0 a sell and 1 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is GSK's EPS forecast?
Analysts forecast $4.72 per share for 2026 (range $4.64 to $4.87); for 2027 the estimate is $4.92.
What is GSK's revenue forecast?
The average revenue estimate for 2026 is $33.9 billion, growth of 3.8%; for 2027 it is $35.5 billion.
When does GSK report earnings?
GSK is expected to report results for the quarter ending September 30, 2026 on October 28, 2026 before the market opens; the EPS estimate is $1.40.
Does GSK usually beat earnings estimates?
GSK reported EPS at or above the analyst estimate in 11 of the last 12 quarters.